Sorrento Therapeutics, Inc. (SRNE.OB) Receives Grant to Support Development of Staph Fighting Therapeutics
Sorrento Therapeutics Inc. Friday announced that it has received an Advanced Technology Small Business Technology Transfer Research (STTR) grant from the National Institute of Allergy and Infectious Diseases to assist Sorrento in its programs to generate and develop novel antibody therapeutics and vaccines to against Staphylococcus aureus (staph) infections. Phase I of the grant is for $300,000 annually for two years, with the possibility of phase II funding of $1 million per year for up to three years thereafter. According to the Centers for Disease Control and Prevention, in 2005 about 94,000 serious staph infections occurred in the U.S., resulting…